The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial

American Journal of Medicine

Volumn 130, Issue 12, 2017, Pages 1415-1422.e4

  Solomon, Daniel H ^a   Husni, M Elaine ^b   Libby, Peter A ^a   Yeomans, Neville D ^c,d   Lincoff, A Michael ^b   Lϋscher, Thomas F ^e   Menon, Venu ^b   Brennan, Danielle M ^b   Wisniewski, Lisa M ^b   Nissen, Steven E ^b   Borer, Jeffrey S ^f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Cox 2 selective inhibitor; Drug toxicity; Nonsteroidal anti inflammatory drug; NSAID; Randomized controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CREATININE; ESOMEPRAZOLE; HEMOGLOBIN; IBUPROFEN; NAPROXEN; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE KIDNEY FAILURE; ADULT; ALL CAUSE MORTALITY; ANALGESIA; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DUODENUM ULCER; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GEOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; INTERMEDIATE RISK PATIENT; INTESTINAL BLEEDING; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; LARGE INTESTINE PERFORATION; LOW DRUG DOSE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEPHROTOXICITY; OSTEOARTHRITIS; PHASE 4 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SMALL INTESTINE PERFORATION; STOMACH OBSTRUCTION; STOMACH ULCER; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; CLINICAL TRIAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS;

EID: 85028592185     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2017.06.028     Document Type: Article

References (17)

1. Ray, W.A., Varas-Lorenzo, C., Chung, C.P., et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2:3 (2009), 155–163.
2. McGettigan, P., Henry, D., Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med, 8(9), 2011, e1001098.
3. Trelle, S., Reichenbach, S., Wandel, S., et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ, 342, 2011, c7086.
4. Wolfe, M.M., Lichtenstein, D.R., Singh, G., Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999), 1888–1899.
5. Solomon, D.H., Rassen, J.A., Glynn, R.J., Lee, J., Levin, R., Schneeweiss, S., The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 170:22 (2011), 1968–1976.
6. Ruschitzka, F., Painful lessons: COX-2 inhibitors, NSAIDs, and hypertension. Curr Hypertens Rep 9:1 (2007), 41–44.
7. Gislason, G.H., Jacobsen, S., Rasmussen, J.N., et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113:25 (2006), 2906–2913.
8. Arfe, A., Scotti, L., Varas-Lorenzo, C., et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ, 354, 2016, i4857.
9. Becker, M.C., Wang, T.H., Wisniewski, L., et al. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 157:4 (2009), 606–612.
10. Nissen, S.E., Yeomans, N.D., Solomon, D.H., et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med 375:26 (2016), 2519–2529.
11. Altman, R., Alarcon, G., Appelrouth, D., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 34:5 (1991), 505–514.
12. Altman, R., Alarcon, G., Appelrouth, D., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 33:11 (1990), 1601–1610.
13. Altman, R., Asch, E., Bloch, D., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29:8 (1986), 1039–1049.
14. Collaboration, A.T., Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:6921 (1994), 81–106.
15. Health, I., National Prescription Audit, Oral NSAID Market. 2013.
16. Hsiao, C.J., Cherry, D.K., Beatty, P.C., Rechtsteiner, E.A., National Ambulatory Medical Care Survey: 2007 summary. Natl Health Stat Report 27 (2010), 1–32.
17. Sun, X., Briel, M., Walter, S.D., Guyatt, G.H., Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ, 340, 2010, c117.